| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 17, 2009
Accepted on June 12, 2009
Charles P. Darby Children's Research Institute, Medical University of South Carolina, Charleston, SC; Bristol Myers Squibb Pharmaceuticals, Syracuse, NY; Henry Ford Hospital, Detroit, Michigan
* To whom correspondence should be addressed. E-mail: reddysv{at}musc.edu.
RANK ligand (RANKL), a critical osteoclastogenic factor expressed in marrow stromal/preosteoblast cells is upregulated in Paget's disease of bone (PDB). We previously demonstrated that heat shock factor-2 (HSF-2) is a downstream target of fibroblast growth factor-2 (FGF-2) signaling to induce RANKL expression in bone marrow stromal/preosteoblast cells. In this study, we identified a 2.5-fold increase in serum FGF-2 levels in patients (n=8) with PDB compared to normal subjects (n=10). We showed that HSF-2 co-immunoprecipitates with heat shock protein-27 (HSP-27) and that FGF-2 stimulation significantly increased phospho-HSP-27 levels in marrow stromal cells. Confocal microscopy revealed HSF-2 co-localization with HSP-27 in unstimulated cells and HSF-2 nuclear translocation upon FGF-2 stimulation. We further show that FGF-2 stimulation significantly increased the levels of p-STAT-1 in these cells. Western blot analysis confirmed that siRNA suppression of STAT-1 significantly decreased (3.2-fold) RANKL expression and promoter activity in FGF-2 stimulated cells. Chromatin immunoprecipitation (ChIP) assay revealed STAT-1 binding to putative motif located far upstream (-8 kb) in the hRANKL gene promoter region. These results suggest STAT-1 is a downstream effector of FGF-2 signaling and that elevated levels of FGF-2 stimulates RANKL expression in PDB.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |